Community-acquired upper respiratory tract infections and the role of third-generation oral cephalosporins

References

• Cartwright K. Pneumococcal disease in western Europe: burden of disease, antibiotic resistance and management. Eur. J. Pediatr.161, 188–195 (2002).
   PubMed Web of Science ®Google Scholar
• Friedland IR, Med M, McCracken GH. Management of infections caused by antibiotic-resistant Streptococcus pneumoniae. N. Engl. J. Med.331(6), 377–382 (1994).
   PubMed Web of Science ®Google Scholar
• Rovers MM. The burden of otitis media. Vaccine26S, G2–G4 (2008).
   Google Scholar
• McCracken GH. Considerations in selecting an antibiotic for treatment of acute otitis media. Pediatr. Infect. Dis.13, 1054–1057 (1994).
   Google Scholar
• Kyaw MH, Lynfield R, Schaffner W et al. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumonia. N. Engl. J. Med.354(14), 1455–1463 (2006).
   PubMed Web of Science ®Google Scholar
• Haddy RI, Perry K, Chacko CE et al. Comparison of incidence of invasive Streptococcus pneumoniae disease among children before and after ntroduction of conjugated pneumococcal vaccine. Pediatr. Infect. Dis.24(4), 320–323 (2005).
   Google Scholar
• Black S, Shinefield H, Bater R et al. Postlicensure surveillance for pneumococcal invasive disease after use of heptavalent pneumococcal conjugate vaccine in Northern California Kaiser Permanente. Pediatr. Infect. Dis.23(6), 485–489 (2004).
   Google Scholar
• Asensi F, De Jose M, Lorente M et al. A pharmacoeconomic evaluation of seven-valent pneumococcal conjugate vaccine in Spain. Value Health7(1), 36–51 (2004).
   PubMed Web of Science ®Google Scholar
• Reinert RR. Pneumococcal conjugate vaccines – a European perspective. Int. J. Med. Microbiol.294, 277–294 (2004).
   PubMedGoogle Scholar
• Paraskakis I, Kafetzis DA, Chrisakis A et al. Serotypes and antimicrobial susceptibilities of 1033 pneumococci isolated from children in Greece during 2001–2004. Clin. Microbiol. Infection12(5), 490–493 (2006).
   PubMedGoogle Scholar
• Käyhty H, Auranen K, Nohynek H, Dagan R, Makela H, Pneumococcal Carriage Group (PneumoCarr). Nasopharyngeal colonization: a target for pneumococcal vaccination. Expert Rev. Vaccines5(5), 651–657 (2006).
   PubMed Web of Science ®Google Scholar
• De Carvalho Gomez H, Muscat M, Monnet DL, Giesecke J, Lopalco PL. Use of seven-valent pneumococcal conjugate vaccine (PCV7) in Europe, 2001–2007. Eurosurveillance14(12), 1–6 (2009).
   Google Scholar
• Brunton S. Current face of acute otitis media: microbiology and prevalence resulting from widespread use of heptavalent pneumococcal conjugate vaccine. Clin. Ther.28(1), 118–123 (2006).
   PubMedGoogle Scholar
• Block SL, Hedrick J, Harrison J et al. Community-wide vaccination with the heptavalent pneumococcal conjugate significantly alters the microbiology of acute otitis media. Pediatr. Infect. Dis.23(9), 829–833 (2004).
   Google Scholar
• Casey JR, Pichichero ME. Changes in frequency and pathogens causing acute otitis media in 1995–2003. Pediatr. Infect. Dis.23(9), 824–828 (2004).
   Google Scholar
• Farrell DJ, Klugman KP, Pichichero M. Increased antimicrobial resistance among nonvaccine serotypes of Streptococcus pneumoniae in the pediatric population after the introduction of 7-valent pneumococcal vaccine in the United States. Pediatr. Infect. Dis.26(2), 123–128 (2007).
   Google Scholar
• Jacobs MR, Felmingham D, Appelbaum PC, Gruneberg RN, Alexander Project Group. The Alexander Project 1998–2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J. Antimicrob. Chemother.52(2), 229–246 (2003).
   PubMed Web of Science ®Google Scholar
• White AR, Kaye C, Poupard J, Pypstra R, Woodnutt G, Wynne B. Augmentin (amoxicillin/clavulanate) in the treatment of community-acquired respiratory tract infection: a review of the continuing development of an innovative antimicrobial agent. J. Antimicrob. Chemother.53(Suppl. 1), i3–i20 (2004).
   PubMed Web of Science ®Google Scholar
• Harrison CJ, Woods C, Stout G, Martin B, Selvarangan R. Susceptibilities of Haemophilus influenzae, Streptococcus pneumoniae, including serotype 19A, and Moraxella catarrhalis paediatric isolates from 2005 to 2007 to commonly used antibiotics. J. Antimicrob. Chemother.63(3), 511–519 (2009).
   PubMedGoogle Scholar
• Jansen WTM, Verel A, Beitsma M, Verhoef J, Milatovic D. Longitudinal European surveillance study of antibiotic resistance of Haemophilus influenzae. J. Antimicrob. Chemother.58, 873–877 (2006).
   PubMed Web of Science ®Google Scholar
• Sader HS, Jones RN. Cefdinir: an oral cephalosporin for the treatment of respiratory tract infections and skin and skin structure infections. Expert Rev. Anti Infect. Ther.5(1), 29–43 (2007).
   PubMed Web of Science ®Google Scholar
• Anzueto A, Bishai WR, Pottumarthy S. Role of oral extended-spectrum cephems in the treatment of acute exacerbations of chronic bronchitis. Diagn. Microbiol. Infect. Dis.57(3 Suppl.), 31S–38S (2007).
   Google Scholar
• De Lalla F. Cefixime in the treatment of upper respiratory tract infections and otitis media. Chemotherapy44(Suppl. 1), 19–23 (1998).
   PubMedGoogle Scholar
• Mitropoulos IF, Rotschafer JC, Rodvold KA. Adverse events associated with the use of oral cephalosporins/cephems. Diagn. Microbiol. Infect. Dis.57, 67S–76S (2007).
   Web of Science ®Google Scholar
• Ahovuo-Saloranta A, Borisenko OV et al. Antibiotics for acute maxillary sinusitis. Cochrane Database Syst. Rev.2, CD000243 (2008).
   Google Scholar
• Salvo F, Polimeni G, Moretti U et al. Adverse drug reactions related to amoxicillin alone and in association with clavulanic acid: data from spontaneous reporting in Italy. J. Antimicrobial. Chemother.60, 121–126 (2007).
   PubMed Web of Science ®Google Scholar
• Owens RC, Donskey CJ, Gaynes RP, Loo VG, Muto CA. Antimicrobial-associated risk factors for Clostridium difficile infection. Clin. Infect. Dis.46(Suppl. 1), S19–S31 (2008).
   PubMed Web of Science ®Google Scholar